INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249601, 'Ferrous sulfate anhydrous', 'Bictegravir', 'Major', 'Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.', 'DDInter', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.', 'Absorption', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295447/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249602, 'Flibanserin', 'Bictegravir', 'Moderate', 'Coadministration with flibanserin may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter.', 'DDInter', 'Caution is advised when flibanserin is prescribed with drugs that are P-gp substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever flibanserin is added to or withdrawn from therapy.', 'Absorption', 'Caution is advised when flibanserin is prescribed with drugs that are P-gp substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295449/', '', 'Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Bromocriptine, Ibuprofen', 'Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249603, 'Fluconazole', 'Bictegravir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295450/', '', 'Tinidazole, Tetracycline, Cefepime, Norfloxacin, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Levofloxacin, Ofloxacin, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Brincidofovir, Elbasvir, Darunavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249604, 'Fosamprenavir', 'Bictegravir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295451/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More', 'Glecaprevir, Cabotegravir, Amprenavir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Oseltamivir, Brincidofovir, Remdesivir, Famciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249605, 'Fosaprepitant', 'Bictegravir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295452/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249606, 'Fosphenytoin', 'Bictegravir', 'Major', 'Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295453/', '', 'Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More', 'Lamivudine, Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249607, 'Fostemsavir', 'Bictegravir', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.', 'Absorption', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295454/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More', 'Lamivudine, Cabotegravir, Maraviroc, Zanamivir, Valaciclovir, Lenacapavir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Stavudine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249608, 'Gefitinib', 'Bictegravir', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.', 'Absorption', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295456/', '', 'Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249609, 'Gemfibrozil', 'Bictegravir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295457/', '', 'Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Probucol, Cerivastatin, Ezetimibe, Niacin, More', 'Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249610, 'Gilteritinib', 'Bictegravir', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.', 'Absorption', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295458/', '', 'Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More', 'Lamivudine, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249611, 'Glasdegib', 'Bictegravir', 'Moderate', 'Coadministration with glasdegib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) efflux transporters.  In vitro data suggest that glasdegib may have the potential to inhibit P-gp (in the gastrointestinal (GI) tract) and BCRP (systemically and in the GI tract) at clinically relevant concentrations, which may result in decreased clearance of concomitantly administered P-gp and BCRP substrates.', 'DDInter', 'Caution is advised if glasdegib is coadministered with drugs that are substrates of P-gp and/or BCRP, particularly those with a narrow therapeutic range.  Clinical and laboratory monitoring should be considered whenever glasdegib is added to or withdrawn from therapy with these drugs, and dosages adjusted as necessary.  Patients should be monitored for the development of adverse effects.', 'Metabolism', 'Caution is advised if glasdegib is coadministered with drugs that are substrates of P-gp and/or BCRP, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295459/', '', 'Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 'Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249612, 'Glycerol phenylbutyrate', 'Bictegravir', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295460/', '', 'Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Nitisinone, Levocarnitine, Laronidase, Imiglucerase, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Telaprevir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249613, 'Griseofulvin', 'Bictegravir', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295461/', '', 'Terbinafine, Salicylic acid, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Terbinafine, Econazole, Flucytosine, Tioconazole, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249614, 'Guanfacine', 'Bictegravir', 'Moderate', 'Coadministration with bictegravir may increase the plasma concentrations of drugs that are substrates of organic cation transporter 2 (OCT2) and multidrug and toxin extrusion transporter 1 (MATE1).  The mechanism is inhibition of OCT2- and MATE1-mediated renal tubular secretion by bictegravir.', 'DDInter', 'Caution is advised when bictegravir is used with drugs that are substrates of OCT2 or MATE1, particularly those with a narrow therapeutic range.  Close monitoring is particularly recommended in patients with moderate renal impairment (CrCl 30 to 59 mL/min) who are to be administered bictegravir and metformin, due to the increased risk of lactic acidosis.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever bictegravir is added to or withdrawn from therapy.', 'Excretion', 'Caution is advised when bictegravir is used with drugs that are substrates of OCT2 or MATE1, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295462/', '', 'Rauwolfia serpentina root, Clonidine, Methyldopa, Deserpidine', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249615, 'Idelalisib', 'Bictegravir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295464/', '', 'Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More', 'Cabotegravir, Simeprevir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Famciclovir, Ribavirin, Tecovirimat, Maribavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249616, 'Imatinib', 'Bictegravir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295465/', '', 'Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Elbasvir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249617, 'Indinavir', 'Bictegravir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295466/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More', 'Glecaprevir, Cabotegravir, Zanamivir, Lenacapavir, Valaciclovir, Telaprevir, Velpatasvir, Rilpivirine, Oseltamivir, Remdesivir, Famciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249618, 'Iron protein succinylate', 'Bictegravir', 'Major', 'Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.', 'DDInter', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.', 'Absorption', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295469/', '', 'Iron sucrose, Cyanocobalamin, Folic acid', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249619, 'Isavuconazonium', 'Bictegravir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295470/', '', 'Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249620, 'Istradefylline', 'Bictegravir', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter.  The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', 'DDInter', 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295471/', '', 'Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249621, 'Itraconazole', 'Bictegravir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295472/', '', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Flucytosine, Anidulafungin', 'Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, Maribavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249622, 'Ivacaftor', 'Bictegravir', 'Moderate', 'Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter.  The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.  The interaction has been studied with midazolam and digoxin, probe substrates for CYP450 3A4 ad P-gp, respectively.', 'DDInter', 'Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295473/', '', 'Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249623, 'Bictegravir', 'Ivosidenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295474/', '', 'Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249624, 'Bictegravir', 'Kaolin', 'Major', 'Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.', 'DDInter', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.', 'Absorption', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295475/', '', 'Pectin, Activated charcoal', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249625, 'Bictegravir', 'Ketoconazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295476/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More', 'Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249626, 'Bictegravir', 'Lapatinib', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.', 'Absorption', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295477/', '', 'Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249627, 'Bictegravir', 'Lasmiditan', 'Moderate', 'Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters.  The proposed mechanism, based on in vitro data, involves decreased clearance due to inhibition of P-gp and BCRP by lasmiditan.', 'DDInter', 'Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible.  If coadministration is required, patients should be carefully monitored for increased adverse reactions of these drugs and dosing adjusted as necessary.', 'Metabolism', 'Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295478/', '', 'Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Ergotamine, Clonidine, Naratriptan, More', 'Lamivudine, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249628, 'Bictegravir', 'Lefamulin', 'Moderate', 'When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor.', 'DDInter', 'Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oral lefamulin is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a moderate CYP450 3A4 inhibitor like lefamulin and for any dosage adjustments that may be required.', 'Metabolism', 'Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295479/', '', 'Tinidazole, Linezolid, Bacitracin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Fosfomycin, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249629, 'Bictegravir', 'Lesinurad', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295482/', '', 'Pegloticase, Febuxostat, Colchicine, Rasburicase, Probenecid, Allopurinol', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Telaprevir, Velpatasvir, Etravirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249630, 'Bictegravir', 'Lomitapide', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.', 'Absorption', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295484/', '', 'Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Probucol, Cerivastatin, Ezetimibe, Niacin, More', 'Paritaprevir, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Etravirine, Oseltamivir, Acyclovir, Brincidofovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249631, 'Bictegravir', 'Lonafarnib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295485/', '', 'Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Nitisinone, Levocarnitine, Laronidase, Imiglucerase, More', 'Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249632, 'Bictegravir', 'Lorlatinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295487/', '', 'Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More', 'Lamivudine, Cabotegravir, Simeprevir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, Elbasvir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249633, 'Bictegravir', 'Magaldrate', 'Major', 'Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.', 'DDInter', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.', 'Absorption', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295488/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249634, 'Bictegravir', 'Magnesium carbonate', 'Major', 'Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.', 'DDInter', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.', 'Absorption', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295491/', '', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Promethazine, Deferoxamine, Levoleucovorin, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249635, 'Bictegravir', 'Magnesium chloride', 'Major', 'Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.', 'DDInter', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.', 'Absorption', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295492/', '', 'Sodium chloride, Sodium sulfate, Calcium chloride, Potassium chloride, Sodium acetate, Arginine, Sodium glycerophosphate, Zinc chloride, Tromethamine, Sodium phosphate, monobasic, Sodium bicarbonate, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249636, 'Bictegravir', 'Magnesium citrate', 'Major', 'Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.', 'DDInter', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.', 'Absorption', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295493/', '', 'Sorbitol, Sulfamethizole, Sodium citrate, Mannitol, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Neomycin, Sodium chloride, Sodium sulfate, Alvimopan, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249637, 'Bictegravir', 'Magnesium gluconate', 'Major', 'Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.', 'DDInter', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.', 'Absorption', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295494/', '', 'Sodium chloride, Sodium sulfate', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249638, 'Bictegravir', 'Magnesium glycinate', 'Major', 'Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.', 'DDInter', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.', 'Absorption', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295495/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249639, 'Bictegravir', 'Magnesium hydroxide', 'Major', 'Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.', 'DDInter', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.', 'Absorption', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295496/', '', 'Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249640, 'Bictegravir', 'Magnesium oxide', 'Major', 'Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.', 'DDInter', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.', 'Absorption', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295499/', '', 'Sodium chloride, Sodium sulfate, Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249641, 'Bictegravir', 'Magnesium sulfate', 'Major', 'Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.', 'DDInter', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.', 'Absorption', 'When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295501/', '', 'Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249642, 'Bictegravir', 'Methylphenobarbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295505/', '', 'Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249643, 'Bictegravir', 'Metformin', 'Moderate', 'Coadministration with bictegravir may increase the plasma concentrations of drugs that are substrates of organic cation transporter 2 (OCT2) and multidrug and toxin extrusion transporter 1 (MATE1).  The mechanism is inhibition of OCT2- and MATE1-mediated renal tubular secretion by bictegravir.', 'DDInter', 'Caution is advised when bictegravir is used with drugs that are substrates of OCT2 or MATE1, particularly those with a narrow therapeutic range.  Close monitoring is particularly recommended in patients with moderate renal impairment (CrCl 30 to 59 mL/min) who are to be administered bictegravir and metformin, due to the increased risk of lactic acidosis.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever bictegravir is added to or withdrawn from therapy.', 'Excretion', 'Caution is advised when bictegravir is used with drugs that are substrates of OCT2 or MATE1, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295506/', '', 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More', 'Cabotegravir, Maraviroc, Zanamivir, Lenacapavir, Telaprevir, Rilpivirine, Etravirine, Cobicistat, Brincidofovir, Remdesivir, Doravirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249644, 'Bictegravir', 'Metreleptin', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295507/', '', 'Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Nitisinone, Levocarnitine, Laronidase, Imiglucerase, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249645, 'Bictegravir', 'Midostaurin', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.', 'Absorption', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295509/', '', 'Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More', 'Lamivudine, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Stavudine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249646, 'Bictegravir', 'Mifepristone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295510/', '', 'Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249647, 'Bictegravir', 'Mitotane', 'Major', 'Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295512/', '', 'Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Telaprevir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249648, 'Bictegravir', 'Modafinil', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295514/', '', 'Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline', 'Lamivudine, Paritaprevir, Cabotegravir, Simeprevir, Zanamivir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, Elbasvir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249649, 'Bictegravir', 'Nafcillin', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295519/', '', 'Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Telaprevir, Oseltamivir, Acyclovir, Brincidofovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249650, 'Bictegravir', 'Naproxen', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.', 'Absorption', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295520/', '', 'Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Bromocriptine, Ibuprofen, Rabeprazole, Indomethacin, Tolazoline, Ketoprofen, Diclofenac, More', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249651, 'Bictegravir', 'Nefazodone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295521/', '', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, More', 'Lamivudine, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Oseltamivir, Cobicistat, Brincidofovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249652, 'Bictegravir', 'Nelfinavir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295522/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More', 'Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, Oseltamivir, Brincidofovir, Remdesivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249653, 'Bictegravir', 'Neratinib', 'Moderate', 'Coadministration with neratinib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter, such as dabigatran, rosuvastatin, sulfasazine, and topotecan.  The proposed mechanisms, based on in vitro data, is decreased clearance due to neratinib-mediated inhibition of BCRP transport protein.', 'DDInter', 'Caution is advised if neratinib is used concomitantly with drugs that are substrates of BCRP transport protein, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever neratinib is added to or withdrawn from therapy with these drugs.  Patients should be monitored for the development of adverse effects.', 'Metabolism', 'Caution is advised if neratinib is used concomitantly with drugs that are substrates of BCRP transport protein, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295523/', '', 'Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More', 'Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249654, 'Bictegravir', 'Nevirapine', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295524/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More', 'Tenofovir alafenamide, Cabotegravir, Zanamivir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, Telbivudine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249655, 'Bictegravir', 'Nifedipine', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.', 'Absorption', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295525/', '', 'Amlodipine, Nisoldipine, Nicardipine, Isradipine, Clevidipine, Levamlodipine, Celecoxib, Nimodipine, Amlodipine, Amlodipine, Propranolol, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Oseltamivir, Brincidofovir, Remdesivir, Elbasvir, Tipranavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249656, 'Bictegravir', 'Nilotinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295526/', '', 'Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249657, 'Bictegravir', 'Olaparib', 'Moderate', 'Based on in vitro inhibition data, coadministration with olaparib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 (e.g., cisapride, ergot alkaloids, fentanyl, lovastatin, oral midazolam, pimozide, quetiapine, simvastatin, triazolam, vinca alkaloids), P-gp (e.g., colchicine, dabigatran, digoxin), breast cancer resistance protein (BCRP) (e.g., rosuvastatin), OATP1B1 (e.g., eluxadoline, glyburide, repaglinide, statins, valsartan), or organic cation transporter 1 or 2 (OCT1, OCT2) (e.g., metformin).  The proposed mechanism is decreased clearance due to inhibition of the corresponding metabolizing enzyme and/or efflux/uptake transporter by olaparib.', 'DDInter', 'Caution is advised if olaparib must be used concomitantly with drugs that are substrates of the affected enzymes or transporters, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever olaparib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if olaparib must be used concomitantly with drugs that are substrates of the affected enzymes or transporters, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295527/', '', 'Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Rilpivirine, Dolutegravir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249658, 'Bictegravir', 'Oritavancin', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295530/', '', 'Tinidazole, Linezolid, Bacitracin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Fosfomycin, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249659, 'Bictegravir', 'Osimertinib', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.', 'Absorption', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295531/', '', 'Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249660, 'Bictegravir', 'Oxcarbazepine', 'Major', 'Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295533/', '', 'Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More', 'Lamivudine, Paritaprevir, Zanamivir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, Voxilaprevir, Tecovirimat, Pibrentasvir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249661, 'Bictegravir', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295535/', '', 'Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249662, 'Bictegravir', 'Pazopanib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295536/', '', 'Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249663, 'Bictegravir', 'Pentobarbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295537/', '', 'Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249664, 'Bictegravir', 'Pexidartinib', 'Moderate', 'Coadministration with pexidartinib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4.  The proposed mechanism is increased clearance due to pexidartinib-mediated induction of CYP450 3A4 isoenzyme.', 'DDInter', 'Concomitant administration of pexidartinib with drugs that are substrates of CYP450 3A4 should generally be avoided, particularly those with a narrow therapeutic range.  The potential for diminished therapeutic effects should be considered when pexidartinib is prescribed in combination with drugs that are substrates of CYP450 3A4.  Dosage adjustments as well as clinical and laboratory monitoring of the CYP450 3A4 substrate drug should be considered whenever pexidartinib is added to or withdrawn from therapy with these drugs.', 'Metabolism', 'Concomitant administration of pexidartinib with drugs that are substrates of CYP450 3A4 should generally be avoided, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295538/', '', 'Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More', 'Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Elbasvir, Famciclovir, Ribavirin, Tecovirimat, Pibrentasvir, Rimantadine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249665, 'Bictegravir', 'Phenobarbital', 'Major', 'Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295539/', '', 'Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More', 'Lamivudine, Paritaprevir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249666, 'Bictegravir', 'Phenylbutazone', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295540/', '', 'Acetylsalicylic acid, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Sulindac, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, Glucosamine, More', 'Lamivudine, Paritaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, Brincidofovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249667, 'Bictegravir', 'Phenytoin', 'Major', 'Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295541/', '', 'Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More', 'Paritaprevir, Zanamivir, Velpatasvir, Brincidofovir, Elbasvir, Famciclovir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, Valganciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249668, 'Bictegravir', 'Pioglitazone', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295542/', '', 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More', 'Tenofovir alafenamide, Cabotegravir, Maraviroc, Zanamivir, Telaprevir, Rilpivirine, Dolutegravir, Cobicistat, Brincidofovir, Famciclovir, Doravirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249669, 'Bictegravir', 'Ponatinib', 'Moderate', 'Based on in vitro inhibition data, coadministration with ponatinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter.  The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by ponatinib.', 'DDInter', 'Caution is advised when ponatinib is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ponatinib is added to or withdrawn from therapy.', 'Metabolism, Absorption, Excretion', 'Caution is advised when ponatinib is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295544/', '', 'Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249670, 'Bictegravir', 'Posaconazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295545/', '', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Flucytosine, Anidulafungin', 'Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Famciclovir, Tipranavir, Darunavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249671, 'Bictegravir', 'Pralsetinib', 'Moderate', 'Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.', 'DDInter', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295546/', '', 'Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More', 'Lamivudine, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Stavudine, Remdesivir, Elbasvir, Famciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249672, 'Bictegravir', 'Prednisolone', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295547/', '', 'Mometasone furoate, Amcinonide, Budesonide, Fluocinolone acetonide, Hydrocortisone butyrate, Hydrocortisone, Fluticasone, Fluocinonide, Methylprednisolone, Betamethasone, Fluorometholone, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Brincidofovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249673, 'Bictegravir', 'Prednisone', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295548/', '', 'Budesonide, Hydrocortisone, Cromoglicic acid, Olsalazine, Sulfasalazine, Betamethasone, Balsalazide, Beclomethasone dipropionate, Mesalazine, Fludrocortisone, Cortisone, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Brincidofovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249674, 'Bictegravir', 'Primidone', 'Major', 'Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295549/', '', 'Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More', 'Lamivudine, Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249675, 'Bictegravir', 'Propafenone', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.', 'Absorption', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295550/', '', 'Lidocaine, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Bretylium, Moricizine, Ibutilide', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249676, 'Bictegravir', 'Quinidine', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.', 'Absorption', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295551/', '', 'Lidocaine, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Bretylium, Moricizine, Ibutilide', 'Lamivudine, Paritaprevir, Glecaprevir, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249677, 'Bictegravir', 'Quinine', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.', 'Absorption', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295552/', '', 'Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249678, 'Bictegravir', 'Ranolazine', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.', 'Absorption', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295553/', '', 'Alprostadil, Indomethacin, Ibuprofen, Ubidecarenone, Ivabradine, Adenosine, Regadenoson', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249679, 'Bictegravir', 'Regorafenib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295554/', '', 'Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249680, 'Bictegravir', 'Reserpine', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.', 'Absorption', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295555/', '', 'Prazosin, Rauwolfia serpentina root, Hydralazine, Clonidine, Guanethidine, Deserpidine, Rauwolfia serpentina root, Clonidine, Methyldopa, Deserpidine', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249681, 'Bictegravir', 'Ribociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295556/', '', 'Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249682, 'Bictegravir', 'Rifabutin', 'Major', 'Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295557/', '', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More', 'Lamivudine, Paritaprevir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, Elbasvir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249683, 'Bictegravir', 'Rifampicin', 'Major', 'Coadministration with rifampin may significantly decrease the plasma concentrations of bictegravir.  The proposed mechanism is rifampin induction of bictegravir metabolism via CYP450 3A4 and uridine diphosphate glucuronosyltransferase (UGT) 1A1.', 'DDInter', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with rifampin is considered contraindicated.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295558/', '', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More', 'Paritaprevir, Zanamivir, Velpatasvir, Elbasvir, Famciclovir, Tecovirimat, Pibrentasvir, Rimantadine, Valganciclovir, Telbivudine, Entecavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249684, 'Bictegravir', 'Rifapentine', 'Major', 'Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.', 'Metabolism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295559/', '', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More', 'Lamivudine, Paritaprevir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249685, 'Bictegravir', 'Ritonavir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295560/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More', 'Paritaprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Oseltamivir, Darunavir, Maribavir, Rimantadine, Elvitegravir, Telbivudine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249686, 'Bictegravir', 'Rofecoxib', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295561/', '', 'Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Sulindac, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, Glucosamine, Oxaprozin, More', 'Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249687, 'Bictegravir', 'Rolapitant', 'Moderate', 'Coadministration with rolapitant may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter.', 'DDInter', 'Concomitant use of rolapitant with drugs that are P-gp substrates should generally be avoided.  If concomitant administration is unavoidable, caution is advised, particularly with drugs that have a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever rolapitant is added to or withdrawn from therapy.', 'Absorption', 'Concomitant use of rolapitant with drugs that are P-gp substrates should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295562/', '', 'Nabilone, Granisetron, Scopolamine, Dronabinol, Dolasetron, Ondansetron, Palonosetron', 'Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Telaprevir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249688, 'Bictegravir', 'Rucaparib', 'Moderate', 'Coadministration with rucaparib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 3A4.  The proposed mechanism is decreased clearance due to rucaparib-mediated inhibition of CYP450 3A4.', 'DDInter', 'Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever rucaparib is added to or withdrawn from therapy with these drugs.  Patients should be monitored for the development of adverse effects.', 'Metabolism', 'Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295563/', '', 'Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 'Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Dolutegravir, Oseltamivir, Acyclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249689, 'Bictegravir', 'Rufinamide', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295564/', '', 'Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Velpatasvir, Etravirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249690, 'Bictegravir', 'Safinamide', 'Moderate', 'Coadministration with safinamide may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter.  The proposed mechanism is decreased clearance due to intestinal BCRP-inhibition by safinamide.', 'DDInter', 'Caution is advised when safinamide is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range such as methotrexate, topotecan, and irinotecan.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever safinamide is added to or withdrawn from therapy.', 'Excretion', 'Caution is advised when safinamide is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range such as methotrexate, topotecan, and irinotecan.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295565/', '', 'Apomorphine, Ropinirole, Opicapone, Cabergoline, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249691, 'Bictegravir', 'Saquinavir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295566/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More', 'Glecaprevir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Oseltamivir, Remdesivir, Famciclovir, Maribavir, Pibrentasvir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249692, 'Bictegravir', 'Sarecycline', 'Moderate', 'Coadministration with sarecycline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter.  The proposed mechanism is decreased clearance in the intestine, kidney, and/or liver due to inhibition of P-gp-mediated efflux by sarecycline.', 'DDInter', 'Caution is advised when sarecycline is used concurrently with drugs that are P-gp substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever sarecycline is added to or withdrawn from therapy.', 'Metabolism, Absorption, Excretion', 'Caution is advised when sarecycline is used concurrently with drugs that are P-gp substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295567/', '', 'Tetracycline, Minocycline, Oxytetracycline, Doxycycline, Omadacycline, Eravacycline, Demeclocycline, Tigecycline', 'Lamivudine, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249693, 'Bictegravir', 'Secobarbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295568/', '', 'Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More', 'Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249694, 'Bictegravir', 'Simeprevir', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.', 'Absorption', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295569/', '', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249695, 'Bictegravir', 'Somapacitan', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295570/', '', 'Lamivudine, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, More', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249696, 'Bictegravir', 'Somatrem', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295571/', '', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 'Lamivudine, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249697, 'Bictegravir', 'Somatotropin', 'Moderate', 'Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295572/', '', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', 'Lamivudine, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249698, 'Bictegravir', 'Sonidegib', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.', 'Absorption', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295573/', '', 'Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249699, 'Bictegravir', 'Sorafenib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.', 'Metabolism', 'Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295574/', '', 'Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (249700, 'Bictegravir', 'Spironolactone', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.', 'DDInter', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.', 'Absorption', 'The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/295576/', '', 'Eplerenone, Amiloride, Triamterene, Finerenone', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 1767369485);
